Maze Therapeutics, Inc.
MAZE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1,187,064 | $538,050 | $482,207 | $698,547 |
| - Cash | $316,773 | $264,541 | $294,374 | $196,812 |
| + Debt | $24,183 | $25,009 | $25,823 | $26,628 |
| Enterprise Value | $894,474 | $298,518 | $213,656 | $528,363 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | -$649 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$29,516 | -$33,030 | -$34,717 | -$29,021 |
| % Margin | – | – | – | – |
| Net Income | -$30,087 | -$33,679 | -$32,786 | -$29,579 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.66 | -0.77 | -0.749 | -0.112 |
| % Growth | 14.3% | -2.9% | -568.4% | – |
| Operating Cash Flow | -$24,642 | -$30,052 | -$29,516 | -$22,452 |
| Capital Expenditures | -$68 | -$393 | -$299 | -$605 |
| Free Cash Flow | -$24,710 | -$30,445 | -$29,815 | -$23,057 |